Yes, CD117 can be targeted for therapy, particularly in cancers where it plays a critical role. Inhibitors of CD117, such as tyrosine kinase inhibitors (TKIs) like imatinib, are used to treat GISTs and other malignancies with aberrant CD117 signaling. These therapies work by blocking the kinase activity of CD117, thereby inhibiting cell proliferation and inducing apoptosis in cancer cells.
